BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19694755)

  • 21. Opioid peptides: simultaneous delta agonism and mu antagonism in somatostatin analogues.
    Bonner GG; Davis P; Stropova D; Ferguson R; Yamamura HI; Porreca F; Hruby VJ
    Peptides; 1997; 18(1):93-100. PubMed ID: 9114458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
    Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
    J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent side-chain to side-chain cyclized dermorphin analogues containing a carbonyl bridge.
    Filip K; Oleszczuk M; Pawlak D; Wojcik J; Chung NN; Schillerc PW; Izdebski J
    J Pept Sci; 2003 Oct; 9(10):649-57. PubMed ID: 14620130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.
    Piekielna J; De Marco R; Gentilucci L; Cerlesi MC; Calo' G; Tömböly C; Artali R; Janecka A
    Biopolymers; 2016 May; 106(3):309-17. PubMed ID: 27038094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20.
    Kleczkowska P; Bojnik E; Leśniak A; Kosson P; Van den Eynde I; Ballet S; Benyhe S; Tourwé D; Lipkowski AW
    Pharmacol Rep; 2013; 65(4):836-46. PubMed ID: 24145077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
    Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH
    J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
    Ananthan S
    AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereospecific synthesis of (2S)-2-methyl-3-(2',6'-dimethyl-4'-hydroxyphenyl)-propionic acid (Mdp) and its incorporation into an opioid peptide.
    Lu Y; Weltrowska G; Lemieux C; Chung NN; Schiller PW
    Bioorg Med Chem Lett; 2001 Feb; 11(3):323-5. PubMed ID: 11212101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.
    Balboni G; Marzola E; Sasaki Y; Ambo A; Marczak ED; Lazarus LH; Salvadori S
    Bioorg Med Chem; 2010 Aug; 18(16):6024-30. PubMed ID: 20637637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel cyclic enkephalin analogue with potent opioid antagonist activity.
    Weltrowska G; Lu Y; Lemieux C; Chung NN; Schiller PW
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4731-3. PubMed ID: 15324897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
    Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
    J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
    Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
    J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a model for the delta opioid receptor pharmacophore. 1. Conformationally restricted Tyr1 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
    Mosberg HI; Lomize AL; Wang C; Kroona H; Heyl DL; Sobczyk-Kojiro K; Ma W; Mousigian C; Porreca F
    J Med Chem; 1994 Dec; 37(25):4371-83. PubMed ID: 7996549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent opioid peptide agonists containing 4'-[N-((4'-phenyl)-phenethyl)carboxamido]phenylalanine (Bcp) in place of Tyr.
    Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Schiller PW
    Chem Biol Drug Des; 2008 Nov; 72(5):337-40. PubMed ID: 19012569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, biological evaluation, and automated docking of constrained analogues of the opioid peptide H-Dmt-D-Ala-Phe-Gly-NH₂ using the 4- or 5-methyl substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one scaffold.
    De Wachter R; de Graaf C; Keresztes A; Vandormael B; Ballet S; Tóth G; Rognan D; Tourwé D
    J Med Chem; 2011 Oct; 54(19):6538-47. PubMed ID: 21870874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclic mu-opioid receptor ligands containing multiple N-methylated amino acid residues.
    Adamska-Bartłomiejczyk A; Janecka A; Szabó MR; Cerlesi MC; Calo G; Kluczyk A; Tömböly C; Borics A
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1644-1648. PubMed ID: 28318942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and electrophysiological characterization of cyclic morphiceptin analogues.
    Pil J; Van der Veken P; Bal G; Augustyns K; Haemers A; Tytgat J
    Biochem Pharmacol; 2004 May; 67(10):1887-95. PubMed ID: 15130765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
    Yamamoto T; Nair P; Jacobsen NE; Davis P; Ma SW; Navratilova E; Moye S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
    J Med Chem; 2008 Oct; 51(20):6334-47. PubMed ID: 18821747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et): effects on opioid receptor binding and activation.
    McFadyen IJ; Ho JC; Mosberg HI; Traynor JR
    J Pept Res; 2000 Mar; 55(3):255-61. PubMed ID: 10727108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.